NYSE:CHEHealthcare
Chemed (CHE) Is Down 13.8% After Weaker 2025 Earnings And Soft 2026 Guidance Has The Bull Case Changed?
Chemed Corporation recently reported fourth-quarter 2025 results showing net income of US$76.75 million and full-year 2025 net income of US$265.24 million, both lower than the prior year, alongside 2026 adjusted earnings guidance of US$23.25–US$24.25 per diluted share.
Despite ongoing share repurchases totaling US$2.62 billion since 2011, investors focused on pressure in VITAS and Roto-Rooter margins, including Medicare Cap constraints and water-restoration write-offs.
We’ll now examine how...